Compare Amgen, Inc. (AMGN) vs Fabrinet (FN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Fabrinet — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Fabrinet trades at $462.92 (market cap $16.88B). The key difference: Amgen, Inc. is far larger — about 11.6× Fabrinet's market cap, and Amgen, Inc. pays a 2.77% dividend while Fabrinet pays none. Which is the better fit depends on your goals.
| AMGN | FN | |
|---|---|---|
Market Cap | $196.12B | $16.88B |
Sector | Health | Technology |
52-Week High | $388.16 | $746.47 |
52-Week Low | $271.18 | $277.04 |
Enterprise Value | $241.41B | $15.94B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Fabrinet (FN) trades at $471.13, down 2.41% over 24 hours, with technical indicators signaling a bearish short-term trend. The stock shows strong fundamentals, with Q1 2026 EPS of $3.72 beating estimates of $3.56, continuing a pattern of earnings outperformance. Revenue growth is robust, projected to rise from $3.42B in 2025 to $4.2B in 2026, while net income margin improves to 9.94%. Analyst sentiment remains highly bullish with a consensus price target of $733.00, though the stock faces near-term technical headwinds and premium valuation multiples.
Fabrinet's outlook is supported by its strategic position in the AI optical supply chain and consistent earnings beats, offering significant upside relative to analyst targets. Key risks include high valuation metrics, datacom supply constraints, and foreign exchange exposure. The stock presents a compelling growth opportunity for investors comfortable with its premium pricing, provided operational execution remains strong amid competitive and macroeconomic challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Fabrinet
Fabrinet provides advanced optical and electromechanical manufacturing services to original equipment manufacturers. It specializes in complex products for telecom, automotive, and medical industries.
Read more on FN →
